

- ✓ **Thalidomide as initial therapy for early-stage myeloma.**
Rajkumar SV, Gertz MA, Dispenzieri A et al.
Leukemia 2003; 17:775-779
- ✓ **Thalidomide as an anti-cancer agent.**
Kumar S, Witzig TE, Rajkumar SV
J Cell Mol Med 2002; 6(2):160-174
- ✓ **Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.**
Tosi P, Zamagni E, Cellini C et al.
Haematologica 2002; 87(4): 408-414
- ✓ **Thalidomide for the treatment of relapsed and refractory multiple myeloma**
Cool R, Herington JD
Pharmacotherapy 2002; 22(8):1019-1028
- ✓ **Thalidomide: Current and potential clinical applications**
Calabrese L, Fleischer AB
Am J Med 2000; 108:487-495
- ✓ **Antitumor activity of thalidomide in refractory multiple myeloma**
Sibghal S, Mehta J, Desikan R et al.
N Engl J Med 1999; 341:1565-1571
- ✓ **Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells.**
Yata K, Otsuki T, Kurebayashi J et al
Int J Oncol 2003; 22:165-173
- ✓ **Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem-cell transplantation: results of an open label phase 2 multicenter study of efficacy, toxicity and biological activity.**
Richardson P, Schlossman R, Jagannath S
Mayo Clin Proc 2004; 79(7): 875-882
- ✓ **Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.**
Mesa R, Elliott M, Schroeder G et al.
Mayo Clin Proc 2004; 79(7): 883-889
- ✓ **Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.**
Kumar S, Gertz M, Dispenzieri A
Mayo Clin Proc 2003; 78:34-39